false 2026-06-30 Q2 0001875091 --12-31 0001875091 2026-01-01 2026-06-30 0001875091 srt:ScenarioForecastMember 2026-09-23 2026-09-23 0001875091 srt:ScenarioForecastMember srt:BoardOfDirectorsChairmanMember 2026-09-23 2026-09-23 0001875091 us-gaap:CommonStockMember srt:ScenarioForecastMember 2026-09-14 0001875091 srt:ScenarioForecastMember 2026-09-14 2026-09-14 0001875091 2025-01-01 2025-06-30 0001875091 nrsn:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-06-30 0001875091 nrsn:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-06-30 0001875091 nrsn:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-06-30 0001875091 nrsn:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-06-30 0001875091 2026-03-26 2026-03-26 0001875091 us-gaap:RestrictedStockUnitsRSUMember 2026-03-26 2026-03-26 0001875091 nrsn:SeveralEmployeesMember 2026-03-26 2026-03-26 0001875091 nrsn:SeveralEmployeesMember 2026-02-23 2026-02-23 0001875091 2026-01-07 2026-01-07 0001875091 nrsn:SeveralEmployeesMember 2026-01-07 2026-01-07 0001875091 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-07-31 0001875091 us-gaap:CommonStockMember 2026-06-01 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-04-01 2026-04-30 0001875091 us-gaap:CommonStockMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001875091 nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember 2024-03-10 2024-03-10 0001875091 us-gaap:CommonStockMember 2026-02-28 0001875091 nrsn:PrefundedWarrantsMember 2026-02-28 0001875091 us-gaap:CommonStockMember nrsn:SalesAgreementMember 2026-01-01 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001875091 2026-04-02 0001875091 2025-06-30 0001875091 2026-06-30 0001875091 2024-12-31 0001875091 2025-12-31 0001875091 us-gaap:RetainedEarningsMember 2025-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001875091 us-gaap:CommonStockMember 2025-06-30 0001875091 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001875091 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001875091 us-gaap:RetainedEarningsMember 2024-12-31 0001875091 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001875091 us-gaap:CommonStockMember 2024-12-31 0001875091 us-gaap:RetainedEarningsMember 2026-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-06-30 0001875091 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001875091 us-gaap:RetainedEarningsMember 2025-12-31 0001875091 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001875091 us-gaap:CommonStockMember 2025-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of September 2026

 

Commission File Number: 001-41084

 

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

 

NeuroSense Therapeutics Ltd.

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 
 

 

Explanatory Note

 

Attached are the Company’s press release providing a business update for the first half of 2026, condensed interim unaudited financial statements and a summary of its operating and financial review and prospects, each as of June 30, 2026, furnished herewith as Exhibits 99.1, 99.2 and 99.3, respectively.

 

This Report on Form 6-K (including the three bullet points following “Upcoming Corporate Highlights for the Remainder of 2026 include:” in Exhibit 99.1 and Exhibits 99.2 and 99.3) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-262480 and 333-289658) and Form F-3 (File No. 333-269306, 333-283656, 333-284051, 333-291122 and 333-293060), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1
 

 

Exhibit Index

 

Exhibit No.   Description
99.1   Press Release dated September 25, 2026
99.2   Condensed Interim Unaudited Financial Statements as of June 30, 2026
99.3   Operating and Financial Review and Prospects as of June 30, 2026
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Label Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Definition Linkbase Document
104   Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NeuroSense Therapeutics Ltd.
     
Date: September 25, 2026 By: /s/ Alon Ben-Noon
    Alon Ben-Noon
    Chief Executive Officer

 

3

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

PRESS RELEASE DATED SEPTEMBER 25, 2026

CONDENSED INTERIM UNAUDITED FINANCIAL STATEMENTS AS OF JUNE 30, 2026

OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2026

XBRL SCHEMA FILE

XBRL CALCULATION FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: ea0306564-6k_neurosense_htm.xml